http://www.dailymail.co.uk/news/art...treatment-series-expensive-failed-trials.html
Dr Karran said pharmaceutical companies were becoming less willing to gamble on dementia treatments.
A number had scaled down their neuroscience teams, notably Astra Zeneca.
The company, which once had a 300-strong neuroscience task force, now ran a 14-person 'virtual' team in Boston that co-ordinated research done by others but conducted none itself.
'It's a legitimate concern,' said Dr Karran. 'A company's role is to have a return on investment. Its board and shareholders exercise certain pressures; that's capitalism.
'On the other hand the medical need is just massive. There's a societal need for these drugs, clearly.
'I think, rather than big pharma doing this by itself, there will have to be more public-private ownership of these massive trials.
'It will require a different way of thinking to bring these drugs forward.'